Rotterdam, The Netherlands (26 June 2025) – IMCD N.V. (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited and Chemistry & Health FZ LLC.
Founded in 1998 and headquartered in Mumbai, India, Trichem has built a strong reputation in the healthcare sector, supplying high-quality active pharmaceutical ingredients, pharmaceutical intermediates, and formulation solutions. The company also provides regulatory assistance for customers serving the highly regulated pharmaceutical markets in India.
With 36 employees, Trichem operates across India and the Middle East, generating annual revenue of approximately INR 1.7 billion (ca. EUR 18 million) for the financial year ended 31 March 2025. About 33% of this revenue comes from commission income.
“With India being a major supplier of the world’s generic drugs, this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients, and reinforces our position in the region’s life-sciences industry,” said Narendra Varde, Managing Director of IMCD India. “Additionally, we are excited to welcome Trichem’s talented team, whose deep market expertise and strong industry relationships will be invaluable to IMCD.”
Chetan Jain, Founder and Promoter of Trichem Group, added: “IMCD and Trichem share a common vision, strong entrepreneurial spirit, and commitment to building lasting partnerships. I am extremely proud of Trichem’s achievements over the past 27 years. Going forward with IMCD’s global presence, and our strong global principal partnerships, I am confident that this business will deliver immense value to our stakeholders.”
– xxx –
About IMCD
IMCD, based in Rotterdam, The Netherlands, is a leading global partner for the distribution and formulation of speciality chemicals and ingredients. IMCD is an expert solutions provider and adds sustainable value to the supply chain. Every day professionals focus on providing the best service through commercial and operational excellence. The company is mindful of the role they play in creating a better planet for all and formulates with consciousness and executes with care, to address business challenges of tomorrow, in partnership and transparency.
In 2024, with over 5,100 employees, IMCD realised revenues of EUR 4,728 million. IMCD N.V.’s shares are traded at Euronext Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.
For further information, please visit www.imcdgroup.com
Media contact
Muriel Werlé
Corporate Communications Director
+31 10 290 86 14
mediarelations@imcdgroup.com
Investor relations contact
Tosca Holtland
Head of Investor Relations
+31 10 290 86 53
ir@imcdgroup.com
Attachment
- PR IMCD acquires Trichem_20250626
- America’s Blood Centers Honors HOSA-Future Health Professionals Lifesaving Impact at 2025 International Leadership Conference - June 26, 2025
- Marksmen Energy Inc. Announces Filing of its Q1 Interim Financial Statements - June 26, 2025
- CareSource launches $300k grant challenge to improve health care access and outcomes in Georgia - June 26, 2025
